Amo Pharma Limited
Clinical trials sponsored by Amo Pharma Limited, explained in plain language.
-
New drug shows promise for rare muscle disease in kids
Disease control CompletedThis study tested a drug called tideglusib against a placebo in 56 children aged 6 to 16 with congenital myotonic dystrophy, a rare genetic muscle disorder. The goal was to see if tideglusib could reduce symptoms like muscle weakness and breathing problems. The trial was complete…
Phase: PHASE2, PHASE3 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug tideglusib tested for rare muscle disease
Disease control CompletedThis phase 2 study tested the safety and effectiveness of tideglusib, an experimental drug, in 16 adolescents and adults with congenital or juvenile-onset myotonic dystrophy type 1. Participants received either 400 mg or 1000 mg of tideglusib daily. The study measured side effect…
Phase: PHASE2 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC